Beam Therapeutics Inc. BEAM
Set alert
At close · Oct 30
After hours · Oct 30, 7:39 PM ET
- YTD
- -1.77%
- 1 year
- +14.41%
- Open
- 28.27
- Prev close
- 28.84
- Mkt cap
- 2.81B
- Vol
- 1.50M
- Avg vol
- 1.83M
- EPS
- -0.68
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 26.43
- High
- 28.80
- Forward P/E
- -5.67
- Beta
- 2.20
- Short ratio
- 13.87
- Inst. own
- 107.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 25.95
- 200-d avg
- 28.18
- 1y target
- 49.38
3M chart
Events in this range
- Aug 4, 2026Earnings: -1.18; estimate -1.11; surprise -6.31%
- Aug 25, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 9, 2026Rating: Wedbush · Outperform → Outperform
- Oct 14, 2026Rating: Wedbush · Outperform → Outperform
- Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 28, 2026Rating: Wedbush · Outperform → Outperform
- Oct 29, 2026Rating: Canaccord Genuity · Buy → Buy
Signals (15)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 3 days ago |
| SMA: Bullish | Oct 27, 2026 | 4 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
Key statistics
- Market cap
- 2.78B
- Enterprise value
- 1.98B
- Trailing P/E
- 0.00
- Forward P/E
- -5.67
- PEG ratio
- 0.00
- Price / sales
- 17.81
- Price / book
- 2.52
- EPS (TTM)
- -0.68
- Beta
- 2.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -55.45%
- Revenue (TTM)
- 156.04M
- Revenue growth
- -94.20%
- Free cash flow
- -241.84M
- Total cash
- 1.15B
- Total debt
- 247.36M
- Return on equity
- -8.18%
- Shares outstanding
- 103.29M
- Short % of float
- 39.28%
- 50-day average
- 25.95
- 200-day average
- 28.18
Analyst view
Consensus: strong buy
- Target (low)
- 26.00
- Target (mean)
- 49.38
- Target (high)
- 80.00
- Strong buy1
- Buy12
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -1.17.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -1.15 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -1.11 | -1.18 | -0.07 | -6.31% |
| May 7, 2026 | Mar 31, 2026 | -0.87 | -0.91 | -0.04 | -4.60% |
| Feb 24, 2026 | Dec 31, 2025 | -1.13 | -0.10 | +1.03 | +91.15% |
| Nov 4, 2025 | Sep 30, 2025 | -0.98 | -1.10 | -0.12 | -12.24% |
| Aug 5, 2025 | Jun 30, 2025 | -1.04 | -1.00 | +0.04 | +3.85% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 28, 2026 | Wedbush | main | Outperform | Outperform |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 14, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 9, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 25, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- beamtx.com
News
- 3 Promising Genomics Stocks to Add to Your Portfolio Now
- Bears Load Up on Ondas, Dutch Bros and 8 More Stocks — Is a Squeeze Brewing?
- Canaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79
- Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?
- Wedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28
- Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript
- Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance
- Beam Therapeutics Announces Initial Data From Its Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia; In The 40 Mg Cohort, Two Patients Achieved 15 Hours Of Controlled Fasting; Safety Profile Of BEAM-301 Consistent With LNP-Based Therapies
- Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
- Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in Stock
Your note
Sign in to keep a note on BEAM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BELLON CHRISTINE | Officer | Sale | Mar 31, 2026 | 109,711 |
| CAVANAGH BETHANY J | Officer and Treasurer | Sale | Mar 31, 2026 | 51,171 |
| CIARAMELLA GIUSEPPE | President | Conversion of Exercise of derivative security | Jun 16, 2026 | 253,911 |
| EMANY SRAVAN KUMAR | Chief Financial Officer | Stock Award(Grant) | Mar 30, 2026 | 105,456 |
| EVANS JOHN M. | Chief Executive Officer | Sale | Jun 29, 2026 | 1,150,200 |
| FMR, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 25, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.21% | 12,609,002 | 339.18M | Jun 29, 2026 |
| Farallon Capital Management LLC | 9.91% | 10,236,396 | 275.36M | Jun 29, 2026 |
| ARK Investment Management, LLC | 9.91% | 10,234,862 | 275.32M | Jun 29, 2026 |
| Blackrock Inc. | 8.71% | 8,997,542 | 242.03M | Jun 29, 2026 |
| State Street Corporation | 5.64% | 5,827,122 | 156.75M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.76% | 4,921,259 | 132.38M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 7.33% | 7,575,673 | 203.79M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.35% | 3,457,347 | 93.00M | Aug 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.33% | 3,441,420 | 92.57M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 3,273,307 | 88.05M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.61% | 2,696,956 | 72.55M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.49% | 2,569,276 | 69.11M | Sep 29, 2026 |